Mirna Therapeutics (NASDAQ: MIRN) recently received a number of ratings updates from brokerages and research firms:

  • 9/21/2016 – Mirna Therapeutics was downgraded by analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating.
  • 9/21/2016 – Mirna Therapeutics was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
  • 9/12/2016 – Mirna Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $6.00 price target on the stock.
  • 9/7/2016 – Mirna Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.75 price target on the stock. According to Zacks, “Mirna Therapeutics, Inc. is a biopharmaceutical company which develops microRNA-based oncology therapeutics. The Company’s pipeline products include MRX34, miR-Rxlet-7, miR-Rx06, miR-Rx07 and miR-Rx16 which are in preclinical trials. Its lead product, MRX34, is a liposome-encapsulated miR-34 mimic indicated for the treatment of primary liver cancer, solid cancers with liver metastases and hematological malignancies. Mirna Therapeutics, Inc. is headquartered in Austin, Texas. “
  • 8/18/2016 – Mirna Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Mirna Therapeutics, Inc. is a biopharmaceutical company which develops microRNA-based oncology therapeutics. The Company’s pipeline products include MRX34, miR-Rxlet-7, miR-Rx06, miR-Rx07 and miR-Rx16 which are in preclinical trials. Its lead product, MRX34, is a liposome-encapsulated miR-34 mimic indicated for the treatment of primary liver cancer, solid cancers with liver metastases and hematological malignancies. Mirna Therapeutics, Inc. is headquartered in Austin, Texas. “
  • 8/16/2016 – Mirna Therapeutics was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $4.50 price target on the stock, down previously from $7.00.
  • 8/16/2016 – Mirna Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $13.00. They now have an “outperform” rating on the stock.
  • 8/15/2016 – Mirna Therapeutics was downgraded by analysts at Leerink Swann from an “outperform” rating to a “market perform” rating. They now have a $4.00 price target on the stock, down previously from $10.00.

Shares of Mirna Therapeutics Inc (NASDAQ:MIRN) traded down 24.39% on Wednesday, reaching $1.86. The company’s stock had a trading volume of 120,037 shares. The firm’s market cap is $38.75 million. The company’s 50 day moving average is $3.17 and its 200-day moving average is $4.12. Mirna Therapeutics Inc has a 1-year low of $1.82 and a 1-year high of $11.01.

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.